+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Learning Disability Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Pre Book Price: $ 5216

Original Price: $ 5795

Learning disability is the disorder of brain to receive, store and respond to the new information. People suffering from learning disabilities have problems in listening, paying attention, reading, speaking, writing, reasoning and performing mathematical operations. Learning disability is actually a group of disorders, not a single disorder which includes dyslexia, dyscalculia, dysgraphia, dyspraxia, attention-deficit hyperactivity disorder (ADHD) and auditory and visual processing disorders. Learning disorders occurs at very young age but they are usually recognized at an early age of five years. 

Currently there are no medicines available for the core treatment of learning disability as the cause is still unkown. However, there are few medicines available which are being prescribed for the treatment and management of ADHD disorder in patients with learning disability. These medicines are segmented into three major categories which include:
  • Stimulants 
  • Non-Stimulants
  • Other medicines
Stimulants are the psychoactive drugs which are focused on inducing temporary improvements in either mental or physical actions or both. These are best studied and highly used medicines to treat ADHD in learning disability treatment market. Common stimulants medications include:
  • Methylphenidate (Ritalin, Concerta)
  • Dexmethylphenidate (Focalin)
  • Amphetamine/Dextroamphetamine (Adderall, Dexedrine, Dextrostat)
  • Lisdexamfetamine (Vyvanse)
Strattera is the only non-stimulant in the learning disability market, approved by the U.S. FDA for the treatment of ADHD. Other medicines which are used for learning disability treatment include:
  • Antidepressants – bupropion (Wellbutrin)
  • Tricyclics – imipramine (Tofranil), nortriptyline (Pamelor, Aventyl), desipramine (Norpramin)
  • Alpha-2 agonists – clondine (Catapres), guanfacine (Tenex)
Besides, there are certain special schools which perform special kind of therapies, to manage the patient’s condition suffering from learning disability. Learning disability therapies include social skills group, solution focused counseling and cognitive behavioral therapy. Social skills group help children learn how to initiate conversations, take turns, make and keep friends and regulate their emotions. According to National Center for Learning Disabilities, 75% of the kids suffering from local disability suffer from problems associated with social skills. Besides, cognitive behavioral therapy is focused on helping the child understand how thoughts of a person affect one’s feelings and behavior. Above all these therapies, it is most essential that parents should handle their child, who is suffering from this disorder, with excessive care and patience.

North America and Europe leads the learning disability treatment market with respect to the medication of ADHD and number of special schools for learning disability children. The U.S. Department of Education has established the law by the name “The Individuals with Disabilities Education Act (IDEA)”, which provides services to learning, disable individuals through its programs. Foundation for people with learning disabilities has also been established in the U.K., which deals with the patient concerns, conduct surveys, awareness programs and research and development activities in context to learning disability. Asia-Pacific is growing faster for learning disability treatment market majorly due to increasing government and private sector initiatives to set up special schools and to spread awareness about the available medicines. 

As for instance, Association of Learning Disabilities of India is working in association with Indian Association of Pediatrics, to improve the conditions of special schools and to spread awareness about the medications available. The major market players which manufacture ADHD medications for learning disability treatment include Pfizer, Inc., Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG and Shire Plc.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Reasons for Buying this Report
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a six-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments


To receive discount, please click on the button below.

Please click on the button below to customize this report.

 
 
Back To Top